Pfizer Inc PFE

$28.19 -0.33 (-1.16%)

Valuation

Market cap
163,694,624,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.42
Forward PE
9.65
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
13,653,755
Avg volume
36,004,695
Day's range
$28.19 – $28.59
Shares out
5,699,674,000
Stochastic %K
74%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Cutlass Oct 1, 5:01 PM
$PFE Here are more details: * Uthmeier filed the lawsuit in state court, alleging that Pfizer(PFE) told consumers its COVID-19 vaccine was safe while failing to disclose potential risks, including heart inflammation and other adverse events. * The lawsuit says Pfizer(PFE) urged people to get the shot to protect others, even though the company never tested whether the vaccine stopped the virus from spreading. * Florida has also accused Pfizer(PFE) of using unfair tactics to dominate the market. * It said the company made more than $80 billion from vaccine sales, then nearly quadrupled the price of the vaccine to a range of $110 to $130 a dose in 2023 from $30. * The state, suing under its consumer protection law, wants a court order to stop the alleged conduct, fines of $10,000 per violation, or $15,000 when seniors or disabled people were harmed, and the return of profits. * Pfizer(PFE) did not immediately respond to Reuters' request for comment.
0 replies
Cutlass Oct 1, 5:00 PM
$PFE Oct 1 (Reuters) - Florida Attorney General James Uthmeier on Thursday filed a lawsuit against Pfizer(PFE) and its CEO, Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of its COVID-19 vaccine.
0 replies
PFElinepfrenzy1990 Oct 1, 4:03 PM 0 replies
Sdwg Oct 1, 3:56 PM
$PFE no pop on the phase 2 data ... somewhat surprising
0 replies
STOCKPICKERTRADER Oct 1, 12:47 PM
$PFE always great to see another product line coming soon - https://finance.yahoo.com/healthcare/articles/pfizers-tilrekimig-shows-significant-skin-063000652.html
0 replies
sam92 Oct 1, 12:21 PM
$PFE Nice👍 https://seekingalpha.com/news/4648933-pfizer-eczema-drug-succeeds-mid-stage-study?utm_content=link-1&position=rta_news_sublogic2_main_0_title&utm_source=seeking_alpha&utm_campaign=rta-stock-news&messageid=2900&mailingid=47742330&serial=47742330.5461&utm_term=47742330.5461&source=email_2900&utm_medium=email
0 replies
Quantumup Oct 1, 11:59 AM
Wedbush reiterated $JBIO Outperform-$47 after the Co. reported preliminary preclinical data for JADE301 at EADV and remained on track to kick off a Phase 1 healthy volunteer study in 4Q26. $PFE $ROIV AZN ARGX OTSKY TVTX VERA VRTX NVS Wedbush said in its note: Preclinical JADE301 data demonstrates ~3x longer half-life vs. dazukibart (PFE, not covered). Additionally, the JADE301 SC and IV doses demonstrated similar time/concentration profiles. Phase 1 results will better inform on human dosing and safety. Bottom line, we see the initial data appearing supportive. No change to our JBIO estimates as we continue to leave JADE301 as upside to our estimates. We look ahead to 2027 as an important turning point for JBIO with multiple readouts lining up including initial JUNIPER Phase 2 JADE101 data.
0 replies
framus_morrigan Oct 1, 8:02 AM
$PFE Wonderful QUARTERLY CANDLE.
2 replies